Search results for "Interstitial Lung Disease"

showing 10 items of 39 documents

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

2018

The identification of reliable predictive biomarkers of efficacy or resistance to immune-oncology (I–O) agents is a major issue for translational research and clinical practice. However, along with PDL1 and molecular features other clinical, radiological and laboratory factors can be considered for the selection of those patients who would not be the best candidate for immune-checkpoint inhibitors (ICPIs). We examined these factors, emerging from the results of currently available studies in non-small cell lung cancer (NSCLC), aiming to provide a useful and manageable tool which can help Oncologists in their everyday clinical practice. A thorough patient evaluation and close clinical monito…

0301 basic medicineOncologymedicine.medical_specialtyLung NeoplasmsImmune-checkpoint inhibitorSettore MED/06 - Oncologia MedicaImmune-checkpoint inhibitorsBiomarkers; Immune-checkpoint inhibitors; Immune-oncology; Non-small cell lung cancer; Predictive factors; Antibodies Monoclonal; B7-H1 Antigen; Biomarkers; CTLA-4 Antigen; Carcinoma Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Patient Selection; Hematology; OncologyAntibodiesB7-H1 Antigen03 medical and health sciences0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungInternal medicineMonoclonalmedicineHumansCTLA-4 AntigenNeutrophil to lymphocyte ratioNon-Small-Cell LungLung cancerHepatitisPerformance statusbusiness.industryPatient SelectionCarcinomaInterstitial lung diseaseAntibodies MonoclonalBronchiolitis obliterans organizing pneumoniaBiomarkerHematologymedicine.diseaseBiomarkers; Immune-checkpoint inhibitors; Immune-oncology; Non-small cell lung cancer; Predictive factors; Hematology; OncologyClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyPredictive factorbusinessBiomarkersImmune-oncologyPredictive factorsProgressive diseaseCritical Reviews in Oncology/Hematology
researchProduct

Familial pulmonary arterial hypertension by KDR heterozygous loss of function

2020

Beyond the major gene BMPR2, several new genes predisposing to PAH have been identified during the last decade. Recently, preliminary evidence of the involvement of the KDR gene was found in a large genetic association study.We prospectively analysed the KDR gene by targeted panel sequencing in a series of 311 PAH patients referred to a clinical molecular laboratory for genetic diagnosis of PAH.Two index cases with severe PAH from two different families were found to carry a loss-of-function mutation in the KDR gene. These two index cases were clinically characterised by low diffusing capacity for carbon monoxide adjusted for haemoglobin (DLCOc) and interstitial lung disease. In one family,…

0301 basic medicinePulmonary and Respiratory MedicineMutationbusiness.industryInterstitial lung diseasemedicine.diseasemedicine.disease_causeMajor gene3. Good healthBMPR2[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system03 medical and health sciences030104 developmental biology0302 clinical medicine030228 respiratory system[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemDiffusing capacityImmunologyMedicinebusinessGeneLoss functionGenetic association
researchProduct

Interstitial lung disease in systemic sclerosis: current and future treatment.

2017

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc–ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis,…

0301 basic medicinemedicine.medical_specialtyPathologyFibrosiImmunologyInterstitial lung diseaseSclerodermaPulmonary function testingSclerodermaPathogenesis03 medical and health sciencesSystemic sclerosi0302 clinical medicineRheumatologyFibrosisPredictive Value of TestsRisk FactorsInternal medicineCase fatality ratemedicineAnimalsHumansImmunology and AllergyMolecular Targeted Therapyskin and connective tissue diseasesLungCause of death030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryInterstitial lung diseaseHematopoietic Stem Cell Transplantationrespiratory systemmedicine.diseaseRheumatologyRespiratory Function Testsrespiratory tract diseasesTreatmentSettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisTreatment OutcomebusinessLung Diseases InterstitialTomography X-Ray ComputedImmunosuppressive AgentsLung Transplantation
researchProduct

Role of MUC1 in idiopathic pulmonary fibrosis: mechanistic insights

2017

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible form of fibrotic interstitial lung disease. MUC1, a membrane-bound O-glycoprotein, is considered as oncogenic molecule by altering signaling pathways involved in cellular processes related to IPF. In previous studies we have observed an up-regulation of MUC1 and its phosphorylated forms in IPF lung tissue. However the exact participation of MUC1 in IPF is currently unknown. Objective: To analyze the mechanism of MUC1-induced lung fibrosis in different cellular and animal models of IPF. Methods: The intracellular mechanism of MUC1 was evaluated by western blot, immunoprecipation and immunofluorescence …

030204 cardiovascular system & hematologyImmunofluorescence03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineWestern blot0502 economics and businessmedicineskin and connective tissue diseasesFibroblastneoplasmsMUC1Lungmedicine.diagnostic_testbusiness.industry05 social sciencesInterstitial lung diseaseWild typerespiratory systemmedicine.diseasedigestive system diseasesrespiratory tract diseasesmedicine.anatomical_structureCancer research050211 marketingbusinessDiffuse Parenchymal Lung Disease
researchProduct

Lung microenvironments and disease progression in fibrotic hypersensitivity pneumonitis

2022

Rationale: Fibrotic hypersensitivity pneumonitis (fHP) is an interstitial lung disease caused by sensitization to an inhaled allergen. Objectives: To identify the molecular determinants associated with progression of fibrosis. Methods: Nine fHP explant lungs and six unused donor lungs (as controls) were systematically sampled (4 samples/lung). According to microcomputed tomography measures, fHP cores were clustered into mild, moderate, and severe fibrosis groups. Gene expression profiles were assessed using weighted gene co-expression network analysis, xCell, gene ontology, and structure enrichment analysis. Gene expression of the prevailing molecular traits was also compared with idiopathi…

AdultGenetic MarkersMalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyExtrinsic Allergic Alveolitisextrinsic allergic alveolitisCritical Care and Intensive Care MedicineSeverity of Illness IndexTranscriptome03 medical and health sciences0302 clinical medicineFibrosisPulmonary fibrosisMedicineHumansLungAged030304 developmental biology0303 health sciencesLungmedicine.diagnostic_testpulmonary fibrosisbusiness.industryGene Expression ProfilingInterstitial lung diseaseReproducibility of ResultsOriginal ArticlesMiddle Agedrespiratory systemmedicine.diseaseFibrosisIdiopathic Pulmonary Fibrosis3. Good healthrespiratory tract diseasesmedicine.anatomical_structureBronchoalveolar lavage030228 respiratory systemCase-Control StudiesDisease ProgressionLinear ModelsFemaleHuman medicineTranscriptomebusinesstranscriptomeHypersensitivity pneumonitisAlveolitis Extrinsic AllergicAmerican journal of respiratory and critical care medicine
researchProduct

Ultrastructural study on human lung in alveolitis versus pulmonary fibrosis

1993

Lung specimens of 21 patients with diffuse interstitial lung disease were examined. The present ultrastructural study outlines the topography and distribution of inflammatory changes in the interstitium, endothelium, and in pneumocytes and phagocytes. Alveolitis is characterized by marked regenerative activity of type II pneumocytes (cuboid metaplasia), intraluminal macrophage accumulation, endothelial swelling, multilamination of the endothelial basement membrane, pericapillary edema, and primarily by cellular infiltrates in the interstitial space. The most prominent feature of the interstitium in pulmonary fibrosis is the lack of immunoinflammatory cells. In some areas there is a marked a…

AdultMalePathologymedicine.medical_specialtyEndotheliumPulmonary FibrosisEpitheliumInterstitial spaceEdemaMacrophages AlveolarDrug DiscoveryPulmonary fibrosismedicineHumansLymphocytesLungGenetics (clinical)InflammationBasement membraneMetaplasiaLungbusiness.industryPneumonia PneumocystisType-II PneumocytesInterstitial lung diseaseGeneral MedicineMiddle Agedrespiratory systemmedicine.diseaseCapillariesmedicine.anatomical_structureImmunologyMolecular MedicineFemalemedicine.symptombusinessAlveolitis Extrinsic AllergicThe Clinical Investigator
researchProduct

Oxygen Radical Production by Alveolar Inflammatory Cells in Idiopathic Pulmonary Fibrosis

1990

Idiopathic pulmonary fibrosis (IPF) is a chronic inflammatory interstitial lung disease characterized by the accumulation of alveolar macrophages (AMs) and neutrophils in the lower respiratory tract, parenchymal cell injury, and fibrosis of the alveolar structure. Reactive oxygen intermediates (ROI) are claimed to be a major cause of tissue damage in IPF; however, the source of ROI has not been unequivocally identified. AMs, as well as neutrophils, are capable of releasing these agents. The contributions of these possible sources are not known. To address this question, we evaluated the spontaneous and stimulated (PMA or zymosan) ROI release of total bronchoalveolar cells and isolated AMs i…

AdultMalePulmonary and Respiratory MedicinePathologymedicine.medical_specialtyFree RadicalsNeutrophilsPrednisolonePulmonary FibrosisCell CountInflammationchemistry.chemical_compoundIdiopathic pulmonary fibrosisFibrosismedicineHumansLungmedicine.diagnostic_testSuperoxide Dismutasebusiness.industryMacrophagesZymosanZymosanInterstitial lung diseaseMiddle Agedrespiratory systemmedicine.diseaserespiratory tract diseasesOxygenPulmonary Alveolimedicine.anatomical_structureBronchoalveolar lavagechemistryLuminescent MeasurementsImmunologyTetradecanoylphorbol AcetateFemalemedicine.symptombusinessBronchoalveolar Lavage FluidRespiratory tractAmerican Review of Respiratory Disease
researchProduct

Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis

2017

Background Interstitial lung disease (ILD) complicates the course of systemic sclerosis (SSc), representing the main cause of death in these patients. The identification of parameters that can predict the early onset and progression of ILD in SSc represents an unmet need in clinical practice. The study was designed to explore whether the surfactant proteins (SP) A and D may be used as noninvasive tools for the early identification of ILD in SSc. Alveolar exhaled nitric oxide (NO) was investigated as a surrogate marker of distal inflammation. Methods Unselected consecutive subjects newly diagnosed with scleroderma and subjects free of respiratory and systemic diseases were recruited. All pat…

AdultMalemedicine.medical_specialtyBreath TestSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologySclerodermaScleroderma03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineDLCOInternal medicineMedicineHumansRespiratory systemLungScleroderma Systemicbusiness.industryPulmonary surfactant-associated proteinMedicine (all)SystemicInterstitial lung diseaseSurfactant protein DNitric oxideGeneral MedicineBiomarkerrespiratory systemmedicine.diseasePulmonary Surfactant-Associated Protein Dmedicine.anatomical_structure030228 respiratory systemBreath Tests030220 oncology & carcinogenesisLung diseaseExhaled nitric oxideFemalebusinessInterstitialLung Diseases InterstitialBiomarkersHuman
researchProduct

The Potential Role of Lung Ultrasound B-Lines for Detection of Lung Radio-Induced Toxicity in Breast Cancer Patients after Radiation Therapy.

2016

Breast cancer patients exposed to doses of radiation after radiotherapy could develop toxicity to lung. Lung ultrasound (LUS) is able to detect interstitial lung disease by the evaluation of B-lines. The aim of our study was to assess the number of B-lines to diagnose lung involvement after chest radiotherapy.We measured LUS B-lines in the treated and contralateral lung of 20 breast cancer patients, 1-3 months after the end of radiotherapy and 1 year after previous LUS. The sum of the B-lines number in the 72 sites on anterior and posterior chest yielded a global B-lines score.B-lines were more numerous in treated (median: 21; 1st-3rd quartiles: 11-31) versus untreated hemithorax (median: 3…

Adultmedicine.medical_specialtymedicine.medical_treatmentBreast Neoplasms030204 cardiovascular system & hematologySensitivity and Specificity03 medical and health sciences0302 clinical medicineBreast cancermedicineHumansRadiology Nuclear Medicine and imagingStage (cooking)Subclinical infectionUltrasonographyLungbusiness.industryInterstitial lung diseaseReproducibility of ResultsMiddle Agedmedicine.diseaseRadiation therapyRadiation Pneumonitismedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisToxicityBiomarker (medicine)Feasibility StudiesFemaleRadiotherapy AdjuvantRadiologyRadiotherapy ConformalCardiology and Cardiovascular MedicinebusinessEchocardiography (Mount Kisco, N.Y.)
researchProduct

Interstitial Lung Disease during ANCA-Associated Vasculitis: A Poor-Prognosis Factor

2018

IF 7.873; International audience

Anti-fibrosing agents[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system[SDV]Life Sciences [q-bio]ANCA-associated vasculitis (AAV)Interstitial lung disease (ILD)ComputingMilieux_MISCELLANEOUS
researchProduct